By Denny Jacob Ligand Pharmaceuticals shares were 21% higher at $89.98 following better-than-expected results in its fourth quarter. The stock is up about.
By Ben Glickman Shares of Verve Therapeutics rose Tuesday after fourth-quarter collaboration revenue came in ahead of expectations. The stock was up 16% to.
By Colin Kellaher The Food and Drug Administration has officially pulled its authorization of the anticancer drug Pepaxto from Swedish biotech Oncopeptides..